List view / Grid view
Mark Quick, Executive Vice-president, Corporate Development at Recipharm, explains how his company has set about becoming a best-in-class provider of contract development and manufacturing solutions to the pharmaceutical industry.
Catalent believes it is essential to share knowledge and experience to improve understanding of drug formulation and delivery challenges and contribute jointly to finding solutions. Will Downie, Senior Vice President, Global Sales and Marketing at Catalent, explains how his company makes a success of this strategy...
Andreas Weiler, Business Unit Head for Emerging Technologies, and Fatma Senkesen, Marketing Intelligence Associate Director, at Lonza, explain how their company has kept in step with industry developments.
Since 2014, AMRI has significantly expanded its service and product range through several acquisitions. Today, it has more than 3,100 employees at 27 locations in the US, UK, Europe and Asia, and it continues to seek new opportunities in areas of complex science. William S Marth, President and Chief Executive…
Twenty five years ago, the European Community took a major step toward political and economic union by adopting the Treaty of Maastricht. The Treaty created the European Union (EU), paving the way for closer economic ties within the Union through the free movement of goods between member states. This opening…
Michel Pettigrew, President of the Executive Board and Chief Operating Officer at Ferring Pharmaceuticals, explains how his company’s decentralised model and focus on entrepreneurialism is helping it to deliver personalised medicine.
Dr Masashi Miyamoto, Director of the Board, Managing Executive Officer, Director of Corporate Strategy & Planning Department at Kyowa Hakko Kirin, explains his company’s five-year mid-term plan (2016-2020) to become a global specialty pharmaceutical company, and other significant initiatives...
Mylan works with industry associations and key stakeholders to improve sustainability of the healthcare system. Jacek Glinka, President, Mylan Europe, explains how...
Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit at Boehringer Ingelheim, tells EPR about some of his company’s achievements that he is most proud of, and describes how it will face the digital challenge...
Marc Princen, Executive Vice President and President Allergan International, explains how Allergan’s novel ethos and innovative approach makes it stand out from the crowd...
From the early use of Hansch parameters and Topliss Trees to today’s computational structure–activity techniques, medicinal chemists have long sought to rationalise drug design to find the quickest and most resource-efficient route to market. But while modern strategies are more reliant on statistical algorithms and vast data libraries, these founding…
The emergence of big data, technological innovations and advancements in scientific research is set to be transformative for the pharmaceutical industry, providing faster access to insights that can drive more informed decision making and accelerate drug development. Dr Chris Barber, CEO of Lhasa Limited, looks at what is next for…
Sanofi has long been at the forefront of the drive to find new, innovative solutions for patients in different therapeutic areas, such as diabetes, cancer, cardiovascular diseases or rare diseases. Marc-Antoine Lucchini, SVP Diabetes and Cardiovascular Europe and Coordinator, Sanofi Europe, discusses some of the company’s achievements...
Microbiological contamination of non-sterile medicinal products is an infrequent, but longstanding and recurring issue. But there is no ‘one size fits all’ approach towards objectionable organisms, says David Elder...
Much rests on the further development of bioanalytical technologies which allow the highest level of sensitivity on small samples, and robust, high reproducibility across large populations. Johan Devenyns, CEO PharmaFluidics, explains further...
